202 related articles for article (PubMed ID: 20136578)
1. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
4. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
5. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
Shah SR; Jean GW; Keisner SV; Ussery SM; Dowell JE
Support Care Cancer; 2012 Jan; 20(1):87-93. PubMed ID: 21197550
[TBL] [Abstract][Full Text] [Related]
6. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
[TBL] [Abstract][Full Text] [Related]
7. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Dincer M; Altundag K; Harputluoglu H; Aksoy S; Cengiz M; Gullu I
Med Oncol; 2008; 25(3):356-9. PubMed ID: 18196480
[TBL] [Abstract][Full Text] [Related]
8. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
Mishra A
J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
[No Abstract] [Full Text] [Related]
10. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
11. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
12. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
14. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid and atrial fibrillation in cancer patients.
Arslan C; Aksoy S; Dizdar O; Dede DS; Harputluoglu H; Altundag K
Support Care Cancer; 2011 Mar; 19(3):425-30. PubMed ID: 20358384
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid treatment at home: safety data from an observational prospective trial.
Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
[TBL] [Abstract][Full Text] [Related]
17. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Nelson A; Fenlon D; Morris J; Sampson C; Harrop E; Murray N; Wheatley D; Hood K; Griffiths G; Barrett-Lee P
Trials; 2013 Oct; 14():325. PubMed ID: 24107437
[TBL] [Abstract][Full Text] [Related]
18. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
[TBL] [Abstract][Full Text] [Related]
19. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
20. [A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events].
Yanae M; Nakao M; Fujiwara K; Kawaguchi A; Tsubaki M; Chiba Y; Morita T; Yamazoe Y; Nishida S
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1093-8. PubMed ID: 22790045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]